NX-2127

Phase 1Small molecule

NX-2127 is one of 3 small molecule programs targeting Relapsed/Refractory B-cell Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory B-Cell MalignanciesRecruiting

Relapsed/refractory B-Cell MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Relapsed/refractory B-Cell Malignancies

#DrugCompanyPhaseTrials

SYS6055

BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd

Phase 1

1 2

NX-2127

NNurix Therapeutics, Inc.

Phase 1

1 3

CD19+

SSt. Jude Children's Research Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Relapsed/refractory B-Cell Malignancies

NCT04830137

Clinical

Trials by Indication[1]

Relapsed/Refractory B-cell Malignancies1 trial

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting·NNurix Therapeutics, Inc.·Phase 1·NCT04830137·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NX-2127. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NX-2127 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NX-2127. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nurix Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNurix Therapeutics, Inc.

NX-2127

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Relapsed/Refractory B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News